PRECIOUS METAL CLAD WIRE FORMULATED FOR AEROSPACE REQUIREMENTS
Anomet Precious Metal Clad Wire Products combine up to three materials to achieve properties such as oxidation- and corrosion-resistance, plus operation at cryogenic to 1200°C temperatures. Featuring 2% or more cladding thickness, these composite clad products are metallurgically bonded; making them much more reliable than plated products that can flake and peel and they are ideal for applications in harsh environments.
Incorporating a gold, silver, palladium or platinum exterior layer, Anomet Precious Metal Clad Wire Products' internal layers can include copper, Inconel®, Kovar®, nickel-iron, niobium, Nitinol®, molybdenum, stainless steel, tantalum, and titanium. Wire is offered in sizes from 0.004" to 0.060" O.D. with claddings from 14% to 38% by weight, and 4.5 to 55 microns, depending upon dia. and the ribbon can be up to 1" wide.
Anomet Precious Metal Clad Wire Products are priced typically 10X less expensive than solid precious metal products.
For more information contact:
Anomet ProductsRobert F. Gallant, Marketing830 Boston TurnpikeShrewsbury, MA 01545 U.S.A.(508) 842-3069 FAX (508) 842-0847e-mail: bgallant@anometproducts.comwww.anometproducts.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/precious-metal-clad-wire-formulated-for-aerospace-requirements-302488727.html
SOURCE Anomet Products
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study. Thank you to the patients and investigators who contributed to the trial." The Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions. In June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. The Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. About the MR-139 3001 Phase 3 StudyThe MR-139 3001 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks. For more information on the MR-139 study design, refer to (NCT06400511). About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing; given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study; the Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions; in June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions; and the Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. View original content to download multimedia: SOURCE Viatris Inc. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
PR Newswire Empowers Brands for AI Search and Strategic Communications with Multichannel Content Amplification
Key features for optimizing content in an AI-driven search environment NEW YORK, July 18, 2025 /PRNewswire/ -- As Large Language Models (LLMs) rapidly transform the search landscape, PR Newswire is empowering communicators to excel through its advanced Multichannel Amplification™ services. PR Newswire helps organizations publish once and reach everywhere, enhancing topical authority and shaping favorable AI-generated summaries. Key Features of PR Newswire's Multichannel Amplification services: Topical Authority: Build and reinforce your brand's presence in authoritative search results by leveraging PR Newswire's industry-leading distribution network, designed to surface expert-driven content across major search engines and media outlets. This is crucial for establishing your brand as a trusted source in an LLM-driven search environment. AI-Friendly Optimization: Structure and distribute press releases that are easily understood and surfaced by AI models, including LLMs. This boosts your brand's visibility and positioning in AI-generated answers and summaries, ensuring your message is accurately interpreted and presented in the evolving search ecosystem. One Message, Multiple Missions: Whether it's media relations, investor updates, brand awareness, or thought leadership, PR Newswire enables you to fulfill multiple communications objectives through a single, strategically crafted piece of content, optimized for how LLMs process information. "PR Newswire's platform is built for today's evolving media landscape, deeply impacted by the rise of LLMs," said Jeff Hicks, Chief Product and Technology Officer at PR Newswire. "We're not just distributing press releases – we're giving brands the tools to influence conversations, rank as topical authorities, and be found in the ways people are searching today, which increasingly means through LLM-powered interfaces." Helpful resources Ready to enhance your brand's visibility in the age of AI? Learn more about PR Newswire's Multichannel Amplification services: Watch PR Newswire's recent on-demand webinar, "From Keywords to Conversations: How AI Search is Reshaping PR," to explore how smart distribution can maximize visibility in the age of AI and LLMs: About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at View original content to download multimedia: SOURCE PR Newswire
Yahoo
2 days ago
- Yahoo
Bank of America Declares Preferred Stock Dividends Payable in August and September 2025
CHARLOTTE, N.C., July 18, 2025 /PRNewswire/ -- Bank of America Corporation today announced the Board of Directors has authorized regular cash dividends on the outstanding shares or depositary shares of the following series of preferred stock: Series of Preferred StockDividend per Share or Depositary Share1Record DatePayment Date Floating Rate Non-Cumulative Preferred Stock, Series E$0.31548July 31August 15 Floating Rate Non-Cumulative Preferred Stock, Series F$1,272.68711August 29September 15 Adjustable Rate Non-Cumulative Preferred Stock, Series G$1,272.68711August 29September 15 Floating Rate Non-Cumulative Preferred Stock, Series 1$0.33385August 15August 28 Floating Rate Non-Cumulative Preferred Stock, Series 2$0.33488August 15August 28 Floating Rate Non-Cumulative Preferred Stock, Series 4$0.34127August 15August 28 Floating Rate Non-Cumulative Preferred Stock, Series 5$0.32475August 1August 21 Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series DD$31.50000August 15September 10 Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series FF$29.3750000September 1September 15 6.000% Non-Cumulative Preferred Stock, Series GG$0.3750000August 1August 18 5.375% Non-Cumulative Preferred Stock, Series KK$0.3359375September 1September 25 5.000% Non-Cumulative Preferred Stock, Series LL$0.3125000September 1September 17 4.250% Non-Cumulative Preferred Stock, Series QQ$0.2656250August 1August 18 4.750% Non-Cumulative Preferred Stock, Series SS$0.2968750August 1August 18 1 Each series of preferred stock, other than Series F and Series G, is represented by depositary shares. Dividend payments are made on a quarterly basis for each series of preferred stock, other than Series DD and Series FF for which dividends are paid on a semi-annual basis. Bank of AmericaBank of America is one of the world's leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 69 million consumer and small business clients with approximately 3,700 retail financial centers, approximately 15,000 ATMs (automated teller machines) and award-winning digital banking with approximately 59 million verified digital users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 4 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and more than 35 countries. Bank of America Corporation stock is listed on the New York Stock Exchange (NYSE: BAC). For more Bank of America news, including dividend announcements and other important information, visit the Bank of America newsroom and register for news email alerts. Investors May Contact: Lee McEntire, Bank of AmericaPhone: Jonathan G. Blum, Bank of America (Fixed Income)Phone: Reporters May Contact: Jocelyn Seidenfeld, Bank of AmericaPhone: View original content to download multimedia: SOURCE Bank of America Corporation
